Functional precision oncology is attracting fresh investment as Swiss startup Prevision Medicine raises $5.4 million to accelerate commercialization of technology that tests cancer drugs directly on a patient’s living tumor cells. The seed round was led by Swiss early-stage investor ACE Ventures, with participation from GoHub Ventures, SICTIC and healthcare-focused angel investors.
The Zurich-based company plans to use the funding to pursue regulatory clearances, strengthen reimbursement coverage and expand operations across Europe. Its strategy reflects growing interest in moving precision oncology beyond genomic predictions toward direct measurement of how an individual patient’s cancer responds to different treatments.
Functional Precision Oncology Tests Living Cancer Cells
Conventional precision oncology frequently relies on genomic and molecular testing to identify mutations that may indicate whether a particular targeted therapy could work.
That approach has transformed cancer care for many patients, but it does not provide actionable treatment options in every case.
The National Cancer Institute notes that most cancer patients currently do not have a genetic mutation that points to a specific targeted treatment. Functional precision medicine attempts to address that limitation by exposing living patient-derived cells or tissues to different therapies and measuring the resulting response.
Prevision Medicine applies this principle through its PrevisionOne platform.
Functional Precision Oncology Uses PrevisionOne
PrevisionOne tests a patient’s living cancer cells against more than 100 drugs and drug combinations.
The process uses automated microscopy and AI-based analysis to monitor how malignant and nonmalignant cells react to different therapies. Prevision says clinicians can receive a ranked treatment report within approximately three days.
Rather than predicting response solely from molecular characteristics, the approach measures what happens when the patient’s cancer cells actually encounter a treatment outside the body.
The company initially focuses heavily on hematological cancers, where viable cells can be collected and tested more readily, while also developing applications for solid tumors.
Pharmacoscopy Provides Scientific Foundation
Prevision’s platform is built around pharmacoscopy, an image-based functional drug screening approach developed through years of academic research.
Pharmacoscopy exposes patient cells to multiple therapies and uses high-throughput microscopy to determine how individual cancer and healthy cells respond.
An earlier clinical study involving patients with aggressive hematological malignancies demonstrated the potential of this strategy. In an interim cohort of 17 patients receiving pharmacoscopy-guided therapy, 15 achieved an overall response compared with four who responded to their previous regimen. Median progression-free survival increased from 5.7 weeks during the prior treatment to 22.6 weeks with the pharmacoscopy-guided approach.
Those findings were generated in a small, single-arm study and therefore require cautious interpretation, but they established an important foundation for further investigation.
Research Continues Beyond Early Trials
Subsequent studies have continued evaluating functional drug profiling in advanced blood cancers.
Research published in Blood Cancer Discovery reported that among 56 patients with advanced aggressive hematologic malignancies treated using pharmacoscopy-guided approaches, 30 experienced a progression-free survival improvement greater than 1.3-fold compared with their previous therapy. Twelve patients experienced progression-free survival lasting more than three times longer than expected for their disease.
Prevision lists additional studies involving acute myeloid leukemia, multiple myeloma, melanoma and glioblastoma among the research supporting its technology.
These studies do not mean functional testing is ready to replace established oncology guidelines. Instead, they support continued research into how direct drug-response measurement might complement existing molecular and clinical information.
Funding Targets Regulatory and Commercial Expansion
The new $5.4 million investment marks a shift from technology development toward broader commercialization.
Prevision says the capital will support regulatory approvals and reimbursement coverage while also expanding operations across Europe. The company currently has operations in Zurich and Lausanne.
Reimbursement will be particularly important.
A clinically promising oncology test must demonstrate not only analytical and clinical performance but also whether its information changes treatment decisions sufficiently to justify its cost.
Functional Precision Oncology Must Prove Value
That economic question becomes especially relevant when cancer patients have several expensive therapeutic options.
If functional testing can identify ineffective treatments before they are administered, it could potentially reduce unnecessary toxicity and spending while directing patients toward therapies more likely to help.
GoHub Ventures argues that this is central to the investment case, particularly for patients who have exhausted guideline-recommended options. However, those economic benefits remain investor and company expectations that will need to be demonstrated through prospective clinical and health-economic evidence.
Payer acceptance may therefore depend on evidence showing that the test improves outcomes or avoids enough ineffective treatment to offset its cost.
AI Helps Make Testing More Scalable
An important part of Prevision’s strategy involves reducing the cost and complexity traditionally associated with pharmacoscopy.
GoHub says Prevision has redesigned sample preparation around Giemsa, a conventional pathology stain, rather than depending exclusively on more expensive fluorescent techniques. The company’s AI analyzes cell morphology to distinguish cancerous from noncancerous cells within these images.
This could make the platform easier for regional laboratories to adopt.
Under the proposed model, partner laboratories can process samples locally while images are sent to Prevision’s cloud-based analytical system. That could allow geographic expansion without requiring Prevision to construct a new specialized laboratory in every market.
Genomics and Functional Testing Could Complement Each Other
Functional precision medicine should not necessarily be viewed as a competitor to genomic oncology.
Genomic testing can identify actionable mutations, biological pathways and targeted therapies. NCI explains that biomarker testing can help clinicians select treatments based on genes, proteins and other characteristics of an individual tumor. However, even when a biomarker matches a therapy, that treatment does not always work because tumor biology is more complex than a single molecular alteration.
Functional testing asks a different question: how do the patient’s living tumor cells respond when directly exposed to treatment?
Combining molecular and functional information could ultimately provide clinicians with a broader evidence base for difficult treatment decisions.
Functional Precision Oncology Enters Commercial Test
Prevision Medicine’s $5.4 million seed round reflects investor confidence in a field moving from academic research toward commercial oncology applications.
The company now faces the harder stage: demonstrating that its technology can be standardized, regulated, reimbursed and integrated into routine treatment decisions across multiple healthcare systems.
Its scientific foundation is notable, but broader adoption will depend on prospective evidence demonstrating clinical utility, cost effectiveness and reproducibility across cancer types.
For functional precision oncology, that represents the next major test.
If live-cell testing can reliably complement genomic profiling while producing actionable results within days, technologies such as PrevisionOne could give oncologists another tool for selecting therapies when conventional biomarkers provide limited guidance.
The latest funding gives Prevision Medicine additional resources to determine whether that promise can move from specialized research settings into scalable real-world cancer care.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed
